Clinical trial · Interventional
A Survivorship Care Plan and Embedded Navigation Tool
Evaluation of the Impact of A Survivorship Care Plan and Embedded Navigation Tool (ASCENT) in Patients With Prostate Cancer Undergoing Curative-Intent Radiotherapy With Concurrent Androgen Deprivation Therapy (ADT)
NCT03424837CI-TRIAL-00052963ASCENTcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a parallel group, multisite prospective clinical study. The purpose of this study is to evaluate whether ASCENT enables patients to adhere to the survivorship guidelines and improves coordination of care to address patient needs.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ASCENT | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Intervention Arm: SoC (standard of care) and ASCENT
- description
- Health care per institutional standard plus ASCENT via the TrueNTH website.
- interventionNames
- Behavioral: ASCENT
- type
- NO_INTERVENTION
- label
- Control Arm: SoC and TrueNRH
- description
- Health care per institutional standard, plus access to the public information on the TrueNTH website; such as the symptom tracker, exercise \& diet, and lived experiences modules.
Primary outcomes (2)
- measure
- Abiding by the survivorship guidelines as measured by making an appointment within 6 months of enrollment OR completing a guideline-based assessment.
- timeFrame
- 6 months
- description
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed diagnosis of prostate adenocarcinoma * Age ≥18 years * Receiving curative intent radiotherapy for prostate cancer (Note: post-operative radiotherapy \[i.e., "adjuvant" or "salvage radiotherapy subsequent to prostatectomy\] is allowed.) * Subjects will be enrolled within two weeks prior to and two weeks after the final fraction of radiotherapy. * Receiving androgen deprivation therapy (ADT) for a duration of ≥3 consecutive months as follows: * GnRH agonist or antagonist (medical castration), with or without an anti-androgen (i.e., bicalutamide, flutamide, nilutamide, etc.), OR * Bilateral orchiectomy (surgical castration) * Technology requirement: candidates must have access to the internet * Able to understand and willing to sign a written informed consent document. * Able to speak and understand English, in the opinion of the treating physician. Exclusion Criteria: * Significant concurrent medical or psychiatric condition that would interfere with the patient's ability to abide by the study protocol or cooperate fully with the protocol requirements, including completion of survey and assessment
References
Publications (0)
Data not yet available
No reference posted for this study.